ArticleBlood cancer journal2019

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.

A Keith Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.